The Company has filed a patent application based on these observations and those data may have broader applicability
JULY 25, 2018
RICHMOND, BC and GUILFORD, CONN., BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) (“Bioasis” or the “Company”), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) for the treatment of CNS disorders, today announced that its lead investigational candidate xB3-001 demonstrated increased brain activity in a pre-clinical mouse microdialysis study.
Bioasis conducted the microdialysis study at Charles River Laboratories Inc.The aim of the study was to evaluate the effect of xB3-001 on cortical brain-related activity in a freely-moving in vivomouse microdialysis study. Brain activity was assessed by examining changes on neurochemical levels induced by the Company’s lead candidate xB3-001 vs. trastuzumab alone.
The study demonstrated that following a single intravenous treatment, xB3-001 elicited significant increases in brain cortical dopamine and serotonin activity levels at 60-90 minutes after treatment. In contrast, trastuzumab alone did not lead to changes in dopamine and serotonin levels. Brain cortex norepinephrine also showed increasing trends at 60-90 minutes after treatment with xB3-001 compared to the trastuzumab control. The neurochemical changes observed with xB3-001 treatment may indicate that xB3 fusions may yield additional benefits for patients with neurodegenerative and oncological diseases.
“In addition to our recently published work with MedImmune, these new data further validated the utility of our xB3 platform technology to increase delivery of existing therapeutic compounds across the blood-brain barrier,” said Mei Mei Tian, Ph.D., vice president, head of external research. “These data strengthen our pre-clinical data set on the utility of the LRP1 receptor mechanism of action for BBB translocation and the robustness of the xB3platform to transport large, complex biological therapies to their target in the brain.”
“We are encouraged by these preliminary data from the microdialysis study as we look to advance our xB3-001 program in HER2+ brain metastases,” said Mark Day, Ph.D., president & chief executive officer. “Robust demonstration of modulation of brain activity can be critical to the translational success for patients in clinical trials. These data continue to help us build our risk mitigation strategy and can improve our probability of success in the clinic if endpoints are congruent across animals and humans.”
The Company has filed a patent application based on the discoveries from this study.
Bioasis also advises investors that an updated version of its corporate presentation containing this information is available for review on its website at www.bioasis.us/investors.
-----------------------------------
Here is a direct link to the Corporate Presentation.
